Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...

Key takeaways Eli Lilly has filed lawsuits against four telehealth companies—Mochi Health, Fella Health, Willow Health, and ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...